Hepcinat Plus 60mg/400mg Tablet

The human body reacts differently to Hepcinat Plus 60mg/400mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the side effects of Hepcinat Plus 60mg/400mg Tablet are mentioned below:

• Headache 
  
• Fever
  
• Chills
  
• Nausea
  
• Insomnia (difficulty in sleeping)
  
• Diarrhea
  
• Fatigue
• Allergic Reactions (Skin rash, Itching, irritability, breathing difficulty)
• Slow heart rate
• Liver issues

• Take the dose of Hepcinat Plus 60mg/400mg Tablet as per your healthcare provider’s prescription.
• Do not stop taking the medicine suddenly unless your doctor tells you to.
• This medicine is given under the strict supervision of a doctor. Do not self-administer.
• Hepcinat Plus 60mg/400mg Tablet can be taken without food or with food. 
• You should not break, crush, or chew the medicine; it should be swallowed as a whole. 

• Hepcinat Plus 60mg/400mg Tablet is made by combining two medicines that are Sofosbuvir and Daclatasvir.
• They both lower the viral load in the body and the viruses in the blood. Daclatasvir inhibits a protein called NS5A, which is an important protein required for the replication of the hepatitis C virus, whereas Sofosbuvir inhibits the NS5B protein, which is also an essential protein in the replication of the hepatitis C virus.
• Hepcinat Plus 60mg/400mg Tablet is a direct-acting antiviral medication that is used to increase the effectiveness in treating HCV.

• Butt Z, Shah SMA. (2024). Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in the Pakistani population - A real-world experience. Pak J Med Sci. 35(2):409-413 - https://pmc.ncbi.nlm.nih.gov/articles/PMC6500802/
• Kapoor R., Kohli A., Sidharthan S. (2024). All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID Synergy Trial. Hepatology. 4(60).
• Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, Malhotra A, Parvez A, Sood A. (2023). Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3, and 4: A Real-Life Experience from India. J Clin Exp Hepatol. 8(1):7-14 - https://pubmed.ncbi.nlm.nih.gov/29743791/
• Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. (2024). Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther. 22(3):225-236 - https://pubmed.ncbi.nlm.nih.gov/27845298/
• Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH. (2023). Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int. 12(4):339-347 - https://pubmed.ncbi.nlm.nih.gov/29663115/
• Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J. (2024). Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. Clin Ther. 38(2):404-12.
• Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. (2024).Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C-Related Decompensated Cirrhosis. J Clin Exp Hepatol. 9(1):4-12.